Notizie AIOM – anno XV
FDA Accepts Resubmission of Lutetium [177Lu] oxodotreotide NDA for GEP-NETs
August 28, 2017 - The FDA has accepted a resubmitted new drug application (NDA) for lutetium oxodotreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Under the Prescription Drug User Fee Act, the FDA is scheduled to make ...Leggi tutto
FDA Grants Frontline Bosutinib Priority Review in CML
August 29, 2017 - The FDA has granted a priority review to a supplemental new drug application (sNDA) for bosutinib for the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). The agency is scheduled to make a final ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul melanoma è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, per ...Leggi tutto
A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer
Salvage radiotherapy (SRT) is a standard of care for men who recur postprostatectomy, and recent randomized trials have assessed the benefit and toxicity of adding hormone therapy (HT) to SRT with differing results. To perform a systematic review of randomized phase III ...Leggi tutto
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic ...Leggi tutto
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
August 24, 2017 - As reported in the Journal of Oncology Practice by Chang et al, for the first time for any type of malignancy, the American Urological Association (AUA), ASCO, American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have ...Leggi tutto
FDA Approval Sought for Frontline Cabozantinib in RCC
August 16, 2017 - A supplemental new drug application (sNDA) has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor. The sNDA is based on ...Leggi tutto
FDA Approves Ibrutinib for GVHD
August 2, 2017 - The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease (cGVHD) following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD. ...Leggi tutto
FDA Approves Inotuzumab Ozogamicin for ALL
August 17, 2017 - The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), based on findings from the phase III INO-VATE trial. The approval comes with a boxed warning for hepatotoxicity ...Leggi tutto